<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82584">
  <stage>Registered</stage>
  <submitdate>7/02/2008</submitdate>
  <approvaldate>8/02/2008</approvaldate>
  <actrnumber>ACTRN12608000072314</actrnumber>
  <trial_identification>
    <studytitle>Bare Metal BifuRcAtion SteNt Clinical Trial in Humans (IP088) With Coronary Stenosis At or Near a Vessel Bifurcation - Safety at 30-Days</studytitle>
    <scientifictitle>Bare Metal Bifurcation Stent Clinical Trial in Humans (IP088) - Safety at 30 Days</scientifictitle>
    <utrn />
    <trialacronym>BRANCH</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Stenosis of Coronary Arteries</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Angiographic placement of a bare metal coronary stent in a lesion at or near a vessel bifurcation.  Stent intended for permanent placement (endothelialization into vessel wall)</interventions>
    <comparator>No Comparator</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>A composite of cardiac death, target vessel myocardial infarction (MI), and clinically driven target vessel revascularization (TVR)</outcome>
      <timepoint>30 Days post-procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>A composite of cardiac death, target vessel MI and clinically driven TVR</outcome>
      <timepoint>6, 9, and 12 months post-procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patient is =/&gt; 18 years old
Acceptable candidate for Percutaneous Coronary Intervention (PCI) and Coronary Artery Bypass Graft (CABG)
Clinical evidence of ischemic heart disease
Female patients with negative pregnancy test
Informed Consent Obtained
Agrees to comply with follow-up evaluations
Single de novo bifurcation lesion in a native coronary artery with specific dimensions
Stenosis =/&gt; 50% and &lt; 100%
Thrombolysis in Myocardial Infarction (TIMI) flow =/&gt; 2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>N/A</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Hypersensitivity  or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, chromium, molybdenum
Platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3
WBC &lt; 3,000 cells/mm3
Serum creatinine level &gt; 170 micromol/L
Evidence of MI within 72 hours of intended trial procedure
Previous stenting in Target Vessel
LVEF &lt; 30%
History of stroke or TIA within 6 months
History of bleeding diathesis or coagulopathy or refusal of blood transfusion
Specific target lesion morphology</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>13/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3168</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Vascular</primarysponsorname>
    <primarysponsoraddress>3576 Unocal Place
Santa Rosa, CA 95403</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Medtronic Vascular</fundingname>
      <fundingaddress>3576 Unocal Place
Santa Rosa, CA 95403</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A prospective multi-center, non-randomized, single arm trial enrolling up to 60 patients with symptomatic ischemic heart disease attributable to a bifurcation lesion that is amenable to percutaneous treatment with stenting.  
A bifurcation lesion must have =/&gt; 50% stenosis in the main branch.
Trial patients may have multiple vessel disease but only a single bifurcation lesion per patient mmay be treated during the trial procedure, with no other lesions of any type treated at this time-point.
Clinical follow-up assessment will be performed at 30-days post procedure.
Patient contact for follow-up assesment will be performed at 6 months, 9 months and 12 months post-procedure</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St. Vincent Hospital (Melbourne)
HREC-D</ethicname>
      <ethicaddress>PO Box 2900
Fitzroy Victoria 3065 Australia</ethicaddress>
      <ethicapprovaldate>19/02/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>5/12/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Ross Prpic</name>
      <address>Pacific Clinical Research Group (PCRG)
PO Box 139
Mosman NSW 2088</address>
      <phone>+61 (0)438 072 765</phone>
      <fax>+61 (0)2 9383 8043</fax>
      <email>ross.prpic@pcrg.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Ross Prpic</name>
      <address>Pacific Clinical Research Group (PCRG)
PO Box 139
Mosman NSW 2088</address>
      <phone>+61 (0)438 072 765</phone>
      <fax>+61 (0)2 9383 8043</fax>
      <email>ross.prpic@pcrg.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lexa Mack</name>
      <address>Medtronic Vascular
3576 Unocal Place
Santa Rosa, CA 95403</address>
      <phone>(707)543-5035</phone>
      <fax>(707)591-7429</fax>
      <email>lexa.mack@medtronic.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>